Prostate cancer, PI3K, PTEN and prognosis.
暂无分享,去创建一个
[1] F. Saad,et al. PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.
[2] Wei Yuan,et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.
[3] Pier Paolo Pandolfi,et al. The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.
[4] Ruedi Aebersold,et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). , 2013, European urology.
[5] W. Sellers,et al. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[6] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[7] M. Foti,et al. Non-genomic loss of PTEN function in cancer: not in my genes. , 2011, Trends in pharmacological sciences.
[8] M. Jeschke. Faculty Opinions recommendation of Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. , 2008 .
[9] M. Mann,et al. Specificity and commonality of the phosphoinositide-binding proteome analyzed by quantitative mass spectrometry. , 2014, Cell reports.
[10] T. Mak,et al. Polarization of Chemoattractant Receptor Signaling During Neutrophil Chemotaxis , 2022 .
[11] W. Cavenee,et al. Advances in Brief Loss of Heterozygosity for 10 q 22 †” lOqterin Malignant Melanoma Progression ' , 2006 .
[12] C. Feschotte,et al. Endogenous viruses: insights into viral evolution and impact on host biology , 2012, Nature Reviews Genetics.
[13] D. Murphy,et al. G Protein Signaling Events Are Activated at the Leading Edge of Chemotactic Cells , 1998, Cell.
[14] G. Adler,et al. TGFβ-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN , 2005, Journal of Cell Science.
[15] William L. Welbourn,et al. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer , 2014, International journal of urology : official journal of the Japanese Urological Association.
[16] R. Shah,et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression , 2009, Modern Pathology.
[17] T. Mak,et al. Retinal degeneration triggered by inactivation of PTEN in the retinal pigment epithelium. , 2008, Genes & development.
[18] Yiling Lu,et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.
[19] P. Carroll,et al. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer , 2015, The Prostate.
[20] M. Loda,et al. Identification of the miR-106b~25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation , 2010, Science Signaling.
[21] P. Pandolfi,et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. , 2009, Cancer cell.
[22] Laurence A. Turka,et al. Cancer-Associated PTEN Mutants Act in a Dominant-Negative Manner to Suppress PTEN Protein Function , 2014, Cell.
[23] Joachim M. Buhmann,et al. Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity , 2016, Scientific Reports.
[24] Xueying Mao,et al. The complexity of prostate cancer: genomic alterations and heterogeneity , 2012, Nature Reviews Urology.
[25] A. Sivachenko,et al. Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.
[26] Jay Shendure,et al. Genome interrupted: sequencing of prostate cancer reveals the importance of chromosomal rearrangements , 2011, Genome Medicine.
[27] Michael C. Ostrowski,et al. Allele-specific tumor spectrum in Pten knockin mice , 2010, Proceedings of the National Academy of Sciences.
[28] Jennifer R. Rider,et al. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. , 2015, Journal of the National Cancer Institute.
[29] J. Brooks,et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.
[30] D. Berney,et al. High‐resolution genome‐wide copy‐number analysis suggests a monoclonal origin of multifocal prostate cancer , 2012, Genes, chromosomes & cancer.
[31] C. Downes,et al. Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression , 2006, Journal of Cell Science.
[32] M. Ittmann,et al. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] Cornelis J. Weijer,et al. PtdIns(3,4,5)P3-Dependent and -Independent Roles for PTEN in the Control of Cell Migration , 2007, Current Biology.
[34] E. Hafen,et al. Living with Lethal PIP3 Levels: Viability of Flies Lacking PTEN Restored by a PH Domain Mutation in Akt/PKB , 2002, Science.
[35] Hong Sun,et al. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. , 1997, Cancer research.
[36] M. Berger,et al. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. , 2012, Neuro-oncology.
[37] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[38] Jing Li,et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.
[39] T. Price,et al. Can we accurately report PTEN status in advanced colorectal cancer? , 2014, BMC Cancer.
[40] W. Gerald,et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.
[41] S. Barry,et al. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models. , 2015, European urology.
[42] Ferdinando Di Cunto,et al. Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs , 2011, Cell.
[43] G. Parmigiani,et al. Evaluating a 4‐marker signature of aggressive prostate cancer using time‐dependent AUC , 2015, The Prostate.
[44] M. Loda,et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.
[45] L. Cantley,et al. PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.
[46] J. Engelman,et al. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. , 2015, Cancer cell.
[47] B. Vogelstein,et al. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations , 2010, Oncogene.
[48] K. Shokat,et al. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. , 2008, The Biochemical journal.
[49] J. Cuzick,et al. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer , 2013, British Journal of Cancer.
[50] P. Pandolfi,et al. Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.
[51] I. Batty,et al. Understanding PTEN regulation: PIP2, polarity and protein stability , 2008, Oncogene.
[52] C. Plass,et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.
[53] B. Eickholt,et al. Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110α/PIK3CA but not by HER2 or mutant AKT1 , 2013, Oncogene.
[54] J. Squire,et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome , 2007, British Journal of Cancer.
[55] C. Mitchell,et al. Regulation of PtdIns(3,4,5)P3/Akt signalling by inositol polyphosphate 5-phosphatases. , 2016, Biochemical Society transactions.
[56] V. Beneš,et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.
[57] S. Tomlins,et al. The prostate cancer genome: perspectives and potential. , 2014, Urologic oncology.
[58] M. Serrano,et al. PTEN recruitment controls synaptic and cognitive function in Alzheimer's models , 2016, Nature Neuroscience.
[59] G. Ruvkun,et al. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. , 1998, Molecular cell.
[60] J. Squire,et al. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration‐resistant prostate cancer , 2012, Histopathology.
[61] M. Ringnér,et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.
[62] G. Barton,et al. PTEN Protein Phosphatase Activity Correlates with Control of Gene Expression and Invasion, a Tumor-Suppressing Phenotype, But Not with AKT Activity , 2012, Science Signaling.
[63] R. Luong,et al. Crosstalking between Androgen and PI3K/AKT Signaling Pathways in Prostate Cancer Cells* , 2014, The Journal of Biological Chemistry.
[64] Paulo A. S. Nuin,et al. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications , 2012, Genes, chromosomes & cancer.
[65] A. Zoubeidi,et al. Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review). , 2014, International journal of oncology.
[66] Hong Wu,et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. , 2007, Cancer cell.
[67] J. Mossong,et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis , 2007, International journal of cancer.
[68] Yiling Lu,et al. Src Family Protein-tyrosine Kinases Alter the Function of PTEN to Regulate Phosphatidylinositol 3-Kinase/AKT Cascades* , 2003, Journal of Biological Chemistry.
[69] M. Müller,et al. PTEN/MMAC1 mutations in prostate cancer , 2000, Prostate Cancer and Prostatic Diseases.
[70] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[71] L. Liaw,et al. SLUG is a direct transcriptional repressor of PTEN tumor suppressor , 2015, The Prostate.
[72] Beth Israel,et al. Decision letter: Replication Study: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology , 2010 .
[73] H. Zentgraf,et al. Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies , 2004, Virchows Archiv.
[74] R. Shah,et al. Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling. , 2015, Human pathology.
[75] J. Weissenbach,et al. Loss of the chromosomal region 10q23-25 in prostate cancer. , 1995, Cancer research.
[76] L. Tran,et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. , 2011, Cancer cell.
[77] Johann S de Bono,et al. Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer , 2009, Clinical Cancer Research.
[78] P. Pandolfi,et al. Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic State , 2012, Cell.
[79] Chris Sander,et al. Copy number alteration burden predicts prostate cancer relapse , 2014, Proceedings of the National Academy of Sciences.
[80] P. Carroll,et al. Analytic Validation of a Clinical-Grade PTEN Immunohistochemistry Assay in Prostate Cancer by Comparison to PTEN FISH , 2016, Modern Pathology.
[81] B. Vanhaesebroeck,et al. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor , 2011, The Biochemical journal.
[82] A. Tan,et al. The Mutational Landscape of Mucosal Melanoma. , 2020, Seminars in cancer biology.
[83] C. Eng,et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome , 1997, Nature Genetics.
[84] T. Roberts,et al. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context , 2014, Proceedings of the National Academy of Sciences.
[85] B. Dai,et al. PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis. , 2015, International journal of clinical and experimental medicine.
[86] A. Ziaee,et al. Role of PTEN gene in progression of prostate cancer. , 2007, Urology journal.
[87] W. Denny,et al. Beta-testing of PI3-kinase inhibitors: is beta better? , 2012, Cancer discovery.
[88] Pier Paolo Pandolfi,et al. Subtle variations in Pten dose determine cancer susceptibility , 2010, Nature Genetics.
[89] Tobias Meyer,et al. Comprehensive identification of PIP3-regulated PH domains from C. elegans to H. sapiens by model prediction and live imaging. , 2008, Molecular cell.
[90] W. Cavenee,et al. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. , 1998, Cancer research.
[91] J. Lindberg,et al. Genetic markers associated with early cancer‐specific mortality following prostatectomy , 2013, Cancer.
[92] Y. Ionov,et al. Par-3 partitioning defective 3 homolog (C. elegans) and androgen-induced prostate proliferative shutoff associated protein genes are mutationally inactivated in prostate cancer cells , 2009, BMC Cancer.
[93] J. Hicks,et al. ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma. , 2016, Human pathology.
[94] H. Frierson,et al. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[95] Frank McCormick,et al. EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma , 2009, Science Signaling.
[96] Leif E. Peterson,et al. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. , 2011, Cancer research.
[97] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[98] B. Leyland-Jones,et al. PI3K-mTOR in Cancer and Cancer Therapy , 2016 .
[99] P. Hawkins,et al. PI3K signalling: the path to discovery and understanding , 2012, Nature Reviews Molecular Cell Biology.
[100] L. Salmena,et al. Phosphoinositide signaling in cancer: INPP4B Akt(s) out. , 2015, Trends in molecular medicine.
[101] I. Batty,et al. Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases. , 2012, Advances in biological regulation.
[102] M. Stratton,et al. The cancer genome , 2009, Nature.
[103] M. Rue,et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities , 2005, Modern Pathology.
[104] H. Frierson,et al. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate , 1998, Oncogene.
[105] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[106] K. Failing,et al. Expression of PTEN in malignant and non‐malignant human prostate tissues: comparison with p27 protein expression , 2004, The Journal of pathology.
[107] Andrew J Armstrong,et al. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. , 2013, Endocrine-related cancer.
[108] K. Nielsen,et al. Is PTEN loss associated with clinical outcome measures in human prostate cancer? , 2008, British Journal of Cancer.
[109] Takashi Kumagai,et al. PTEN promoter is methylated in a proportion of invasive breast cancers , 2004, International journal of cancer.
[110] Andrea Califano,et al. A Molecular Signature Predictive of Indolent Prostate Cancer , 2013, Science Translational Medicine.
[111] Martha E. Zeeman,et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. , 2011, Cancer cell.
[112] Simon T Barry,et al. Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. , 2015, Cancer cell.
[113] P. Nelson,et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.
[114] T. Mak,et al. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. , 2000, Cancer research.
[115] 森田 良治. Common regions of deletion on chromosomes 5q, 6q, and 10q in renal cell carcinoma , 1994 .
[116] D. Troyer,et al. Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation , 2007, Clinical Cancer Research.
[117] C. Cooper,et al. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer , 2012, Modern Pathology.
[118] K. Claes,et al. Prostate cancer in Cowden syndrome: somatic loss and germline mutation of the PTEN gene. , 2011, Cancer genetics.
[119] Daniel J. Freeman,et al. Genetic background controls tumor development in PTEN-deficient mice. , 2006, Cancer research.
[120] Jianfeng Xu,et al. PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients , 2011, Clinical Cancer Research.
[121] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.
[122] J. Hicks,et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy , 2012, Cancer.
[123] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[124] Barry Fine,et al. Activation of the PI3K Pathway in Cancer Through Inhibition of PTEN by Exchange Factor P-REX2a , 2009, Science.
[125] C. Sander,et al. Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.
[126] M. Nykter,et al. Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[127] A. Sivachenko,et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.
[128] Paul Workman,et al. Drugging PI3K in cancer: refining targets and therapeutic strategies , 2015, Current opinion in pharmacology.
[129] M. Wigler,et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[130] A. Evans,et al. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade , 2013, Modern Pathology.
[131] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[132] D. Amadori,et al. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone , 2015, British Journal of Cancer.
[133] Gerald C. Chu,et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.
[134] G. Ruvkun,et al. Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. , 1998, Genes & development.
[135] W. K. Alfred Yung,et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.
[136] L. Cantley,et al. Regulation of mTORC1 by PI3K signaling. , 2015, Trends in cell biology.
[137] Julian Downward,et al. Akt/PKB localisation and 3′ phosphoinositide generation at sites of epithelial cell–matrix and cell–cell interaction , 1999, Current Biology.
[138] W. Isaacs,et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. , 1998, Cancer research.
[139] Chiang-Ching Huang,et al. Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer , 2016, Oncotarget.
[140] Lewis C. Cantley,et al. AKT/PKB Signaling: Navigating Downstream , 2007, Cell.
[141] A. Toker,et al. Signaling specificity in the Akt pathway in biology and disease. , 2014, Advances in biological regulation.
[142] O. Halvorsen,et al. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[143] Sarah H. Johnson,et al. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer , 2016, Modern Pathology.
[144] Paulo A. S. Nuin,et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. , 2006, Cancer Genetics and Cytogenetics.
[145] H. Stoop,et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi‐allelic gene deletion , 2006, The Journal of pathology.
[146] A. Toker,et al. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis , 2016, Oncotarget.
[147] J. Hicks,et al. In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading , 2016, Virchows Archiv.
[148] R. Rocha,et al. Best practice for PTEN gene and protein assessment in anatomic pathology. , 2014, Acta histochemica.
[149] J. Rinn,et al. Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer , 2016, Nature Communications.
[150] R. Silverman,et al. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers , 2011, Oncogene.
[151] G. Stamp,et al. RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms , 2013, Cell.
[152] Anirban Datta,et al. PTEN-Mediated Apical Segregation of Phosphoinositides Controls Epithelial Morphogenesis through Cdc42 , 2007, Cell.
[153] A. Efeyan,et al. Pten positively regulates brown adipose function, energy expenditure, and longevity. , 2012, Cell metabolism.
[154] L. Joshua-Tor,et al. PTEN functions by recruitment to cytoplasmic vesicles. , 2015, Molecular cell.
[155] P. Pandolfi,et al. A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? , 2011, Cell.
[156] Matteo Benelli,et al. Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.
[157] M. Wigler,et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[158] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[159] E. Petricoin,et al. Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis , 2015, PloS one.
[160] Yong Li,et al. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. , 2015, Critical reviews in oncology/hematology.
[161] J. Wu,et al. The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities , 2016 .
[162] R. Prinjha,et al. PTEN couples Sema3A signalling to growth cone collapse , 2006, Journal of Cell Science.
[163] Tomohiko Maehama,et al. The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.
[164] Ximing J. Yang,et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten mice , 2006 .
[165] Alice T. Loo,et al. PTEN-deficient cancers depend on PIK3CB , 2008, Proceedings of the National Academy of Sciences.
[166] PI3K Inhibitor Improves PFS in BELLE-2 Trial. , 2016, Cancer discovery.
[167] J. Hicks,et al. PTEN Loss is Associated with Upgrading of Prostate Cancer from Biopsy to Radical Prostatectomy , 2014, Modern Pathology.
[168] Hong Wu,et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. , 2003, Cancer cell.
[169] Hao Wu,et al. PDZ domains of Par-3 as potential phosphoinositide signaling integrators. , 2007, Molecular cell.
[170] M. Gleave,et al. Loss of PTEN is associated with progression to androgen independence , 2006, The Prostate.
[171] M. Rubin,et al. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity , 2012, Histopathology.
[172] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[173] F. Brimo,et al. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity , 2012, BMC Cancer.